Chemoresistance, Cancer Stem Cells, and miRNA Influences: The Case for Neuroblastoma

Analytical Cellular Pathology

Volumn 2015, Issue , 2015, Pages

  Buhagiar, Alfred ^a   Ayers, Duncan ^b,c  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b UNIVERSITY OF MALTA   (Malta)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE; DNA; MICRORNA;

APOPTOSIS; CANCER STEM CELL; CANCER THERAPY; COMPUTER ASSISTED TOMOGRAPHY; DRUG RESISTANCE; GENE; GENE MUTATION; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MYCN GENE; NEUROBLASTOMA; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REVIEW; STROMA CELL; GENETICS; METABOLISM; PATHOLOGY; TREATMENT OUTCOME;

DRUG RESISTANCE, NEOPLASM; HUMANS; MICRORNAS; NEOPLASTIC STEM CELLS; NEUROBLASTOMA; TREATMENT OUTCOME;

EID: 84938150762     PISSN: 22107177     EISSN: 22107185     Source Type: Journal    
DOI: 10.1155/2015/150634     Document Type: Review

References (112)

1. S. Gherardi, E. Valli, D. Erriquez, and G. Perini, "MYCNmediatedtranscriptional repression in neuroblastoma: theother side of the coin, " Frontiers in Oncology, vol. 3, article 42, 2013.
2. MD Anderson Cancer Center, Neuroblastoma Cancer Facts Information, 2015, http://www. mdanderson. org/patient-andcancer-information/cancer-information/cancer-types/neuroblastoma/index. html.
3. Neuroblastoma in children, 2013, http://www. macmillan. org. uk/Cancerinformation/Cancertypes/Childrenscancers/Typesofchildrenscancers/Neuroblastoma. aspx.
4. J. Buechner and C. Einvik, "N-myc and noncoding RNAs inneuroblastoma, " Molecular Cancer Research, vol. 10, no. 10, pp. 1243-1253, 2012.
5. R. P. Castleberry, "Neuroblastoma, " European Journal of Cancer, vol. 33, no. 9, pp. 1430-1438, 1990.
6. L. Moreno, L. V. Marshall, and A. D. J. Pearson, "At thefrontier of progress for paediatric oncology: the neuroblastomaparadigm, " British Medical Bulletin, vol. 108, no. 1, pp. 173-188, 2013.
7. F. Bourdeaut, D. Trochet, I. Janoueix-Lerosey et al. , "Germlinemutations of the paired-like homeobox 2B (PHOX2B) gene inneuroblastoma, " Cancer Letters, vol. 228, no. 1-2, pp. 51-58, 2005.
8. J. M. Maris, "Recent advances in neuroblastoma, " The NewEngland Journal of Medicine, vol. 362, no. 23, pp. 2202-2211, 2010.
9. Y. P. Mossé, M. Laudenslager, L. Longo et al. , "Identification ofALK as a major familial neuroblastoma predisposition gene, "Nature, vol. 455, no. 7215, pp. 930-935, 2008.
10. T. R. Webb, J. Slavish, R. E. George et al. , "Anaplastic lymphomakinase: role in cancer pathogenesis and small-moleculeinhibitor development for therapy, " Expert Review of AnticancerTherapy, vol. 9, no. 3, pp. 331-356, 2009.
11. Y. Chen, J. Takita, Y. L. Choi et al. , "Oncogenicmutations ofALKkinase in neuroblastoma, " Nature, vol. 455, no. 7215, pp. 971-974, 2008.
12. S. C. Bresler, D. A. Weiser, P. J. Huwe et al. , "ALK mutationsconfer differential oncogenic activation and sensitivity to ALKinhibition therapy in neuroblastoma, " Cancer Cell, vol. 26, no. 5, pp. 682-694, 2014.
13. J. M. Maris andK. K. Matthay, "Molecular biology of neuroblastoma, "Journal of Clinical Oncology, vol. 17, no. 7, pp. 2264-2279, 1999.
14. M. A. Hayat, Ed. , Neuroblastoma, vol. 1 of Pediatric Cancer, Springer, Dordrecht, The Netherlands, 2012.
15. M. Yoshimoto, S. R. C. de Toledo, E. M. Monteiro Caran et al. , "MYCNgene amplification, "TheAmerican Journal of Pathology, vol. 155, no. 5, pp. 1439-1443, 1999.
16. K. De Preter, J. Vandesompele, P. Heimann et al. , "Humanfetal neuroblast and neuroblastoma transcriptome analysis confirmsneuroblast origin and highlights neuroblastomacandidategenes, " Genome Biology, vol. 7, no. 9, article R84, 2006.
17. L. J. Valentijn, J. Koster, F. Haneveld et al. , "Functional MYCNsignature predicts outcome of neuroblastoma irrespective ofMYCN amplification, " Proceedings of the National Academy ofSciences of the United States of America, vol. 109, no. 47, pp. 19190-19195, 2012.
18. L. M. Hansford, W. D. Thomas, J. M. Keating et al. , "Mechanismsof embryonal tumor initiation: distinct roles for MycN expressionand MYCN amplification, " Proceedings of the NationalAcademy of Sciences of the United States of America, vol. 101, no. 34, pp. 12664-12669, 2004.
19. J. J. Molenaar, R. Domingo-Fernández, M. E. Ebus et al. , "LIN28B induces neuroblastoma and enhances MYCN levelsvia let-7 suppression, " Nature Genetics, vol. 44, no. 11, pp. 1199-1206, 2012.
20. J. Yu, M. A. Vodyanik, K. Smuga-Otto et al. , "Induced pluripotentstem cell lines derived from human somatic cells, " Science, vol. 318, no. 5858, pp. 1917-1920, 2007.
21. J. M. Shohet, "Redefining functional MYCN gene signatures inneuroblastoma, " Proceedings of theNationalAcademy of Sciencesof the United States of America, vol. 109, no. 47, pp. 19041-19042, 2012.
22. P. Mestdagh, E. Fredlund, F. Pattyn et al. , "MYCN/c-MYCinducedmicroRNAs repress coding gene networks associatedwith poor outcome inMYCN/c-MYC-activated tumors, " Oncogene, vol. 29, no. 9, pp. 1394-1404, 2010.
23. F. Zhi, R. Wang, Q. Wang et al. , "MicroRNAs in neuroblastoma:small-sized players with a large impact, " NeurochemicalResearch, vol. 39, no. 4, pp. 613-623, 2014.
24. C. Bottino, A. Dondero, F. Bellora et al. , "Natural killer cellsand neuroblastoma: tumor recognition, escape mechanisms, and possible novel immunotherapeutic approaches, " Frontiersin Immunology, vol. 5, article 56, 2014.
25. National Cancer Institute, Neuroblastoma Treatment, 2015, http://www. cancer. gov/cancertopics/pdq/treatment/neuroblastoma/HealthProfessional/page9.
26. S. Mueller and K. K. Matthay, "Neuroblastoma: biology andstaging, " Current Oncology Reports, vol. 11, no. 6, pp. 431-438, 2009.
27. G. M. Brodeur, J. Pritchard, F. Berthold et al. , "Revisions ofthe international criteria for neuroblastoma diagnosis, stagingand response to treatment, " Progress in Clinical and BiologicalResearch, vol. 385, pp. 363-369, 1994.
28. T. Monclair, G. M. Brodeur, P. F. Ambros et al. , "The InternationalNeuroblastoma Risk Group (INRG) staging system: anINRG Task Force report, " Journal of Clinical Oncology, vol. 27, no. 2, pp. 298-303, 2009.
29. R. C. Lee, R. L. Feinbaum, and V. Ambros, "The C. elegansheterochronic gene lin-4 encodes small RNAs with antisensecomplementarity to lin-14, " Cell, vol. 75, no. 5, pp. 843-854, 1993.
30. G. Di Leva, M. Garofalo, and C. M. Croce, "MicroRNAs incancer, " Annual Review of Pathology, vol. 9, pp. 287-314, 2014.
31. R. W. Carthew and E. J. Sontheimer, "Origins and mechanismsof miRNAs and siRNAs, " Cell, vol. 136, no. 4, pp. 642-655, 2009.
32. F. L. Kisseljov, "MicroRNAs and cancer, "Molecular Biology, vol. 48, no. 2, pp. 197-206, 2014.
33. S. Volinia, G. A. Calin, C.-G. Liu et al. , "A microRNA expressionsignature of human solid tumors defines cancer gene targets, "Proceedings of the National Academy of Sciences of the UnitedStates of America, vol. 103, no. 7, pp. 2257-2261, 2006.
34. X. Wang, L. Cao, Y. Wang, X. Wang, N. Liu, and Y. You, "Regulation of let-7 and its target oncogenes (review), "OncologyLetters, vol. 3, no. 5, pp. 955-960, 2012.
35. E. Mogilyansky and I. Rigoutsos, "The miR-17/92 cluster: acomprehensive update on its genomics, genetics, functionsand increasingly important and numerous roles in health anddisease, " Cell Death and Differentiation, vol. 20, no. 12, pp. 1603-1614, 2013.
36. X. Chen, B. Hao, G. Han et al. , "miR-372 regulates gliomacell proliferation and invasion by directly targeting PHLPP2, "Journal of Cellular Biochemistry, vol. 116, no. 2, pp. 225-232, 2015.
37. Y. C. Chan, J. Banerjee, S. Y. Choi, and C. K. Sen, "miR-210: themaster hypoxamir, " Microcirculation, vol. 19, no. 3, pp. 215-223, 2012.
38. P. Tsukerman, R. Yamin, E. Seidel et al. , "MiR-520d-5p directlytargets TWIST1 and downregulates the metastamiR miR-10b, "Oncotarget, vol. 5, no. 23, pp. 12141-12150, 2014.
39. L. Ma, J. Teruya-Feldstein, and R. A. Weinberg, "Tumourinvasion and metastasis initiated by microRNA-10b in breastcancer, " Nature, vol. 449, no. 7163, pp. 682-688, 2007.
40. D. B. Longley and P. G. Johnston, "Molecular mechanisms ofdrug resistance, " Journal of Pathology, vol. 205, no. 2, pp. 275-292, 2005.
41. D. Ayers and A. Nasti, "Utilisation of nanoparticle technologyin cancer chemoresistance, " Journal of Drug Delivery, vol. 2012, Article ID 265691, 12 pages, 2012.
42. T. R. Wilson, D. B. Longley, and P. G. Johnston, "Chemoresistancein solid tumours, " Annals of Oncology, vol. 17, supplement10, pp. x315-x324, 2006.
43. J.-P. Gillet and M. M. Gottesman, "Mechanisms of multidrugresistance in cancer, " in Multi-Drug Resistance in Cancer, vol. 596 of Methods in Molecular Biology, pp. 47-76, Humana Press, Clifton, NJ, USA, 2010.
44. M. Rebucci and C. Michiels, "Molecular aspects of cancer cellresistance to chemotherapy, " Biochemical Pharmacology, vol. 85, no. 9, pp. 1219-1226, 2013.
45. A. K. Nagaraja, C. J. Creighton, Z. Yu et al. , "A link between mir-100 and FRAP1/mTOR in clear cell ovarian cancer, " MolecularEndocrinology, vol. 24, no. 2, pp. 447-463, 2010.
46. M. R. Abedini, E. J. Muller, R. Bergeron, D. A. Gray, and B. K. Tsang, "Akt promotes chemoresistance in human ovariancancer cells by modulating cisplatin-induced, p53-dependentubiquitination of FLICE-like inhibitory protein, " Oncogene, vol. 29, no. 1, pp. 11-25, 2010.
47. H. Wu, Y. Cao, D. Weng et al. , "Effect of tumor suppressor genePTEN on the resistance to cisplatin in human ovarian cancercell lines and related mechanisms, " Cancer Letters, vol. 271, no. 2, pp. 260-271, 2008.
48. G. Gadea, M. de Toledo, C. Anguille, and P. Roux, "Loss of p53promotes RhoA-ROCK-dependent cell migration and invasionin 3D matrices, " Journal of Cell Biology, vol. 178, no. 1, pp. 23-30, 2007.
49. N. Arsic, G. Gadea, E. Lagerqvist et al. , "The p53 isoform133p53 promotes cancer stem cell potential, " Stem CellReports, vol. 4, no. 4, pp. 531-540, 2015.
50. P. A. J. Muller, P. T. Caswell, B. Doyle et al. , "Mutant p53 drivesinvasion by promoting integrin recycling, " Cell, vol. 139, no. 7, pp. 1327-1341, 2009.
51. D. Lai, S. Visser-Grieve, andX. Yang, "Tumour suppressor genesin chemotherapeutic drug response, " Bioscience Reports, vol. 32, no. 4, pp. 361-374, 2012.
52. W. B. Nagengast, T. H. O. Munnink, E. C. F. Dijkers et al. , "Multidrug resistance in oncology and beyond: from imagingof drug efflux pumps to cellular drug targets, " Methods inMolecular Biology, vol. 596, pp. 15-31, 2010.
53. D. Hanahan and R. A. Weinberg, "Hallmarks of cancer: the nextgeneration, " Cell, vol. 144, no. 5, pp. 646-674, 2011.
54. S. Ghavami, M. Hashemi, S. R. Ande et al. , "Apoptosis andcancer: mutations within caspase genes, " Journal of MedicalGenetics, vol. 46, no. 8, pp. 497-510, 2009.
55. F. H. Igney and P. H. Krammer, "Death and anti-death: tumourresistance to apoptosis, " Nature Reviews Cancer, vol. 2, no. 4, pp. 277-288, 2002.
56. P. Vaupel and A. Mayer, "Hypoxia and anemia: effects ontumor biology and treatment resistance, " Transfusion Cliniqueet Biologique, vol. 12, no. 1, pp. 5-10, 2005.
57. P. Vaupel and A. Mayer, "Hypoxia in cancer: significance andimpact on clinical outcome, " Cancer and Metastasis Reviews, vol. 26, no. 2, pp. 225-239, 2007.
58. J.-P. Cosse andC. Michiels, "Tumour hypoxia affects the responsivenessof cancer cells to chemotherapy and promotes cancerprogression, " Anti-Cancer Agents inMedicinal Chemistry, vol. 8, no. 7, pp. 790-797, 2008.
59. R. Straussman, T. Morikawa, K. Shee et al. , "Tumour microenvironmentelicits innate resistance to RAF inhibitors throughHGF secretion, " Nature, vol. 487, no. 7408, pp. 500-504, 2012.
60. Y. Mao, E. T. Keller, D. H. Garfield, K. Shen, and J. Wang, "Stromal cells in tumor microenvironment and breast cancer, "Cancer andMetastasis Reviews, vol. 32, no. 1-2, pp. 303-315, 2013.
61. R. Lanza and A. Atala, Eds. , Essentials of Stem Cell Biology, Academic Press, Amsterdam, The Netherlands, 3rd edition, 2013.
62. K. Takahashi, K. Tanabe, M. Ohnuki et al. , "Induction ofpluripotent stem cells from adult human fibroblasts by definedfactors, " Cell, vol. 131, no. 5, pp. 861-872, 2007.
63. A. Bongso, Stem Cells: From Bench to Bedside, E. H. Lee, Ed. , World Scientific Publishing, Hackensack, NJ, USA, 2nd edition, 2010.
64. T. Lapidot, C. Sirard, J. Vormoor et al. , "A cell initiating humanacute myeloid leukaemia after transplantation into SCID mice, "Nature, vol. 367, no. 6464, pp. 645-648, 1994.
65. P. Borst, "Cancer drug pan-resistance: pumps, cancer stem cells, quiescence, epithelial to mesenchymal transition, blocked celldeath pathways, persisters or what" Open Biology, vol. 2, no. 5, Article ID 120066, 2012.
66. S. J. Morrison and J. Kimble, "Asymmetric and symmetric stemcelldivisions in development and cancer, " Nature, vol. 441, no. 7097, pp. 1068-1074, 2006.
67. L. Shahriyari and N. L. Komarova, "Symmetric vs. asymmetricstem cell divisions: an adaptation against cancer" PLoS ONE, vol. 8, no. 10, Article ID e76195, 2013.
68. Z. Yu, T. G. Pestell, M. P. Lisanti, andR. G. Pestell, "Cancer stemcells, " International Journal of Biochemistry and Cell Biology, vol. 44, no. 12, pp. 2144-2151, 2012.
69. I. Ischenko, H. Seeliger, M. Schaffer, K.-W. Jauch, and C. J. Bruns, "Cancer stem cells: how can we target them" CurrentMedicinal Chemistry, vol. 15, no. 30, pp. 3171-3184, 2008.
70. S. Chiba, "Notch signaling in stem cell systems, " Stem Cells, vol. 24, no. 11, pp. 2437-2447, 2006.
71. H. J. Kraft, S. Mosselman, H. A. Smits et al. , "Oct-4 regulatesalternative platelet-derived growth factor receptor genepromoter in human embryonal carcinoma cells, " Journal ofBiological Chemistry, vol. 271, no. 22, pp. 12873-12878, 1996.
72. L. Gao, Y. Yang, H. Xu et al. , "MiR-335 functions as a tumorsuppressor in pancreatic cancer by targeting OCT4, " TumourBiology, vol. 35, no. 8, pp. 8309-8318, 2014.
73. P. A. Beachy, S. S. Karhadkar, and D. M. Berman, "Tissue repairand stem cell renewal in carcinogenesis, " Nature, vol. 432, no. 7015, pp. 324-331, 2004.
74. L. Li andW. B. Neaves, "Normal stemcells and cancer stem cells:the niche matters, " Cancer Research, vol. 66, no. 9, pp. 4553-4557, 2006.
75. P. Neveu, M. J. Kye, S. Qi et al. , "MicroRNA profiling reveals twodistinct p53-related human pluripotent stem cell states, " CellStem Cell, vol. 7, no. 6, pp. 671-681, 2010.
76. M. M. Sherry, A. Reeves, J. K. Wu, and B. H. Cochran, "STAT3is required for proliferation and maintenance of multipotencyin glioblastoma stem cells, " Stem Cells, vol. 27, no. 10, pp. 2383-2392, 2009.
77. D. M. Hsu, S. Agarwal, A. Benham et al. , "G-CSF receptorpositive neuroblastoma subpopulations are enriched inchemotherapy-resistant or relapsed tumors and are highlytumorigenic, " Cancer Research, vol. 73, no. 13, pp. 4134-4146, 2013.
78. M. M. Gottesman, T. Fojo, and S. E. Bates, "Multidrug resistancein cancer: role of ATP-dependent transporters, " Nature ReviewsCancer, vol. 2, no. 1, pp. 48-58, 2002.
79. T. Zheng, J. Wang, X. Chen, and L. Liu, "Role of microRNA inanticancer drug resistance, " International Journal of Cancer, vol. 126, no. 1, pp. 2-10, 2010.
80. Y.-Z. Pan, M. E. Morris, and A.-M. Yu, "MicroRNA-328negatively regulates the expression of breast cancer resistanceprotein (BCRP/ABCG2) in human cancer cells, " MolecularPharmacology, vol. 75, no. 6, pp. 1374-1379, 2009.
81. H. Zhu, H. Wu, X. Liu et al. , "Role of MicroRNA miR-27a andmiR-451 in the regulation of MDR1/P-glycoprotein expressionin human cancer cells, " Biochemical Pharmacology, vol. 76, no. 5, pp. 582-588, 2008.
82. O. Kovalchuk, J. Filkowski, J. Meservy et al. , "Involvementof microRNA-451 in resistance of the MCF-7 breast cancercells to chemotherapeutic drug doxorubicin, "Molecular CancerTherapeutics, vol. 7, no. 7, pp. 2152-2159, 2008.
83. M. Dean, T. Fojo, and S. Bates, "Tumour stem cells and drugresistance, " Nature Reviews Cancer, vol. 5, no. 4, pp. 275-284, 2005.
84. A. Gisel, M. Valvano, I. G. El Idrissi et al. , "MiRNAs for thedetection of multidrug resistance: overview and perspectives, "Molecules, vol. 19, no. 5, pp. 5611-5623, 2014.
85. Y. Shi, J. Wang, Z. Xin et al. , "Transcription factors andmicroRNA-co-regulated genes in gastric cancer invasion in exvivo, " PLoS ONE, vol. 10, no. 4, Article IDe0122882, 2015.
86. G. A. Calin, C. Sevignani, C. D. Dumitru et al. , "HumanmicroRNA genes are frequently located at fragile sites andgenomic regions involved in cancers, " Proceedings of theNational Academy of Sciences of the United States of America, vol. 101, no. 9, pp. 2999-3004, 2004.
87. L. Fontana, M. E. Fiori, S. Albini et al. , "Antagomir-17-5p abolishesthe growth of therapy-resistant neuroblastoma throughp21 and BIM, " PLoS ONE, vol. 3, no. 5, Article ID e2236, 2008.
88. H. Mei, Z.-Y. Lin, and Q.-S. Tong, "The roles of microRNAs inneuroblastoma, " World Journal of Pediatrics, vol. 10, no. 1, pp. 10-16, 2014.
89. J. Lovén, N. Zinin, T. Wahlström et al. , "MYCN-regulatedmicroRNAs repress estrogen receptor-alpha (ESR1) expressionand neuronal differentiation in human neuroblastoma, " Proceedingsof the National Academy of Sciences of the United Statesof America, vol. 107, no. 4, pp. 1553-1558, 2010.
90. R. L. Stallings, "MicroRNA involvement in the pathogenesisof neuroblastoma: potential for microRNA mediated therapeutics, "Current Pharmaceutical Design, vol. 15, no. 4, pp. 456-462, 2009.
91. P. Mestdagh, A.-K. Boström, F. Impens et al. , "The miR-17-92microRNA cluster regulates multiple components of the TGF-pathway in neuroblastoma, " Molecular Cell, vol. 40, no. 5, pp. 762-773, 2010.
92. Y. Chen, Y.-H. Tsai, Y. Fang, and S.-H. Tseng, "Micro-RNA-21regulates the sensitivity to cisplatin in human neuroblastomacells, " Journal of Pediatric Surgery, vol. 47, no. 10, pp. 1797-1805, 2012.
93. M. Guidi, M. Muinos-Gimeno, B. Kagerbauer, E. Mart, X. Estivill, and Y. Espinosa-Parrilla, "Overexpression of miR-128specifically inhibits the truncated isoformofNTRK3 and upregulatesBCL2 in SH-SY5Y neuroblastoma cells, " BMC MolecularBiology, vol. 11, article 95, 2010.
94. A. Swarbrick, S. L. Woods, A. Shawet al. , "MiR-380-5p repressesp53 to control cellular survival and is associated with poor outcomein MYCN-amplified neuroblastoma, " Nature Medicine, vol. 16, no. 10, pp. 1134-1140, 2010.
95. H. Qu, L. Zheng, J. Pu et al. , "miRNA-558 promotes tumorigenesisand aggressiveness of neuroblastoma cells throughactivating the transcription of heparanase, " Human MolecularGenetics, vol. 24, no. 9, pp. 2539-2551, 2015.
96. L. Samaraweera, K. B. Grandinetti, R. Huang, B. A. Spengler, and R. A. Ross, "MicroRNAs define distinct human neuroblastomacell phenotypes and regulate their differentiation andtumorigenicity, " BMC Cancer, vol. 14, article 309, 2014.
97. A. M. Lozier, M. E. Rich, A. P. Grawe et al. , "Targetingornithine decarboxylase reverses the LIN28/Let-7 axis andinhibits glycolytic metabolism in neuroblastoma, " Oncotarget, vol. 6, no. 1, pp. 196-206, 2015.
98. H. Zhang, M. Qi, S. Li et al. , "MicroRNA-9 targetsmatrixmetalloproteinase14 to inhibit invasion, metastasis, and angiogenesisof neuroblastoma cells, " Molecular Cancer Therapeutics, vol. 11, no. 7, pp. 1454-1466, 2012.
99. W. C. S. Cho, "OncomiRs: the discovery and progress ofmicroRNAs in cancers, " Molecular Cancer, vol. 6, article 60, 2007.
100. A. Bottoni, D. Piccin, F. Tagliati, A. Luchin, M. C. Zatelli, andE. C. D. Uberti, "miR-15a and miR-16-1 down-regulation inpituitary adenomas, " Journal of Cellular Physiology, vol. 204, no. 1, pp. 280-285, 2005.
101. S. Moncini, A. Salvi, P. Zuccotti et al. , "The role ofmiR-103 andmiR-107 in regulation of CDK5R1 expression and in cellularmigration, " PLoS ONE, vol. 6, no. 5, Article ID e20038, 2011.
102. P. Zuccotti, C. Colombrita, S. Moncini et al. , "HnRNPA2/B1 andnELAV proteins bind to a specific U-rich element in CDK5R13-UTR and oppositely regulate its expression, " Biochimica etBiophysica Acta-Gene RegulatoryMechanisms, vol. 1839, no. 6, pp. 506-516, 2014.
103. L.-C. Cheng, E. Pastrana, M. Tavazoie, and F. Doetsch, "MiR-124 regulates adult neurogenesis in the subventricular zone stemcell niche, " Nature Neuroscience, vol. 12, no. 4, pp. 399-408, 2009.
104. X. Cao, S. L. Pfaff, and F. H. Gage, "A functional study of miR-124 in the developing neural tube, " Genes & Development, vol. 21, no. 5, pp. 531-536, 2007.
105. I. Y. Cheung, T. A. Farazi, I. Ostrovnaya et al. , "DeepMicroRNAsequencing reveals downregulation of miR-29a in neuroblastomacentral nervous system metastasis, " Genes Chromosomesand Cancer, vol. 53, no. 10, pp. 803-814, 2014.
106. S. Das, N. Foley, K. Bryan et al. , "MicroRNAmediates DNAdemethylationevents triggered by retinoic acid during neuroblastomacell differentiation, " Cancer Research, vol. 70, no. 20, pp. 7874-7881, 2010.
107. P. Laneve, L. Di Marcotullio, U. Gioia et al. , "The interplaybetween microRNAs and the neurotrophin receptortropomyosin-related kinase C controls proliferation of humanneuroblastoma cells, " Proceedings of the National Academy ofSciences of theUnited States ofAmerica, vol. 104, no. 19, pp. 7957-7962, 2007.
108. J. Ryan, A. Tivnan, J. Fay et al. , "MicroRNA-204 increasessensitivity of neuroblastoma cells to cisplatin and is associatedwith a favourable clinical outcome, " British Journal of Cancer, vol. 107, no. 6, pp. 967-976, 2012.
109. J. Qiao, S. Lee, P. Paul et al. , "MiR-335 and miR-363 regulation ofneuroblastoma tumorigenesis andmetastasis, " Surgery, vol. 154, no. 2, pp. 226-233, 2013.
110. P. E. Blower, J.-H. Chung, J. S. Verducci et al. , "MicroRNAsmodulate the chemosensitivity of tumor cells, " Molecular CancerTherapeutics, vol. 7, no. 1, pp. 1-9, 2008.
111. J. Wang, J. Chen, P. Chang et al. , "MicroRNAs in plasma ofpancreatic ductal adenocarcinoma patients as novel bloodbasedbiomarkers of disease, " Cancer Prevention Research, vol. 2, no. 9, pp. 807-813, 2009.
112. F. H. Sarkar, Ed. , MicroRNA Targeted CancerTherapy, Springer, New York, NY, USA, 2014.